HUP0203750A2 - IX Faktor/IXa faktor ellenanyagok és ellenanyag származékok - Google Patents

IX Faktor/IXa faktor ellenanyagok és ellenanyag származékok

Info

Publication number
HUP0203750A2
HUP0203750A2 HU0203750A HUP0203750A HUP0203750A2 HU P0203750 A2 HUP0203750 A2 HU P0203750A2 HU 0203750 A HU0203750 A HU 0203750A HU P0203750 A HUP0203750 A HU P0203750A HU P0203750 A2 HUP0203750 A2 HU P0203750A2
Authority
HU
Hungary
Prior art keywords
factor
antibody derivatives
ixa antibodies
antibodies
factor ixa
Prior art date
Application number
HU0203750A
Other languages
English (en)
Inventor
Friedrich Dorner
Falko-Guenter Falkner
Randolf Kerschbaumer
Friedrich Scheiflinger
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3516408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0203750(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of HUP0203750A2 publication Critical patent/HUP0203750A2/hu
Publication of HUP0203750A3 publication Critical patent/HUP0203750A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya a IX-es faktor/aktivált IX-es faktor (IXa faktor)elleni ellenanyag vagy ellenanyag származék, ami fokozza a IXa faktorpro-koaguláns aktivitását. Ó
HU0203750A 1999-09-14 2000-09-13 Factor ix/factor ixa antibodies and antibody derivatives HUP0203750A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0157699A AT411997B (de) 1999-09-14 1999-09-14 Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
PCT/EP2000/008936 WO2001019992A2 (en) 1999-09-14 2000-09-13 FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES

Publications (2)

Publication Number Publication Date
HUP0203750A2 true HUP0203750A2 (hu) 2003-02-28
HUP0203750A3 HUP0203750A3 (en) 2005-01-28

Family

ID=3516408

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203750A HUP0203750A3 (en) 1999-09-14 2000-09-13 Factor ix/factor ixa antibodies and antibody derivatives

Country Status (15)

Country Link
US (2) US7033590B1 (hu)
EP (1) EP1220923B1 (hu)
JP (2) JP4313531B2 (hu)
CN (1) CN1390258A (hu)
AT (2) AT411997B (hu)
AU (1) AU780775B2 (hu)
CA (1) CA2384660A1 (hu)
CZ (1) CZ2002935A3 (hu)
DE (1) DE60035356T2 (hu)
ES (1) ES2288873T3 (hu)
HU (1) HUP0203750A3 (hu)
PL (1) PL354976A1 (hu)
RU (1) RU2002109586A (hu)
SK (1) SK3662002A3 (hu)
WO (1) WO2001019992A2 (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
JP5438880B2 (ja) * 2003-10-10 2014-03-12 中外製薬株式会社 機能蛋白質を代替する二種特異性抗体
JP5490734B2 (ja) * 2003-10-10 2014-05-14 中外製薬株式会社 機能蛋白質を代替する二種特異性抗体
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2006109592A1 (ja) * 2005-04-08 2006-10-19 Chugai Seiyaku Kabushiki Kaisha 血液凝固第viii因子の機能代替抗体
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
US8598321B2 (en) 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
PL3078743T3 (pl) * 2007-09-28 2020-11-02 Portola Pharmaceuticals, Inc. Antidotum dla inhibitorów czynnika XA i sposoby ich stosowania
TWI541020B (zh) 2008-04-17 2016-07-11 巴克斯歐塔公司 生物活性胜肽
CA2732003A1 (en) 2008-07-31 2010-02-04 James D. Marks Antibodies that neutralize botulinum neurotoxins
JP2009292822A (ja) * 2009-07-23 2009-12-17 Chugai Pharmaceut Co Ltd 機能蛋白質を代替する二種特異性抗体
WO2011080322A1 (en) 2009-12-30 2011-07-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
WO2012047427A2 (en) 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
MX355060B (es) * 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
PL2717898T3 (pl) 2011-06-10 2019-06-28 Bioverativ Therapeutics Inc. Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
PL220297B1 (pl) * 2012-11-07 2015-10-30 Wrocławskie Ct Badań Eit & Spółka Z Ograniczoną Odpowiedzialności& Epitop i jego zastosowanie
DK3050896T3 (da) 2013-09-27 2021-07-19 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
WO2016160618A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
US20190119385A1 (en) * 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
EP3458477A1 (en) * 2016-05-16 2019-03-27 Baxalta Incorporated Anti-factor ix padua antibodies
CN109661241A (zh) 2016-09-06 2019-04-19 中外制药株式会社 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
AU2017331739A1 (en) * 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
CR20190297A (es) * 2016-11-23 2019-11-01 Bioverativ Therapeutics Inc Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
BR112019015611A2 (pt) 2017-02-01 2020-03-17 Novo Nordisk A/S Anticorpos pró-coagulantes
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
MX2020002710A (es) 2017-09-29 2020-07-20 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo.
BR112020010016A2 (pt) * 2017-11-22 2020-11-10 Novartis Ag agentes de ligação de reversão para anticorpos antifator xi/xia e usos dos mesmos
CN109837303A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种敲除pd1的靶向cd317的嵌合抗原受体t细胞及其制备方法和应用
CN109836496A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向cd317的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
AU2019313550B2 (en) 2018-08-01 2024-02-08 Novo Nordisk A/S Improved procoagulant antibodies
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
BR112021012065A2 (pt) 2018-12-21 2021-12-07 Kymab Ltd Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia
JP2023512089A (ja) 2020-01-30 2023-03-23 ノヴォ ノルディスク アー／エス 二重特異性第ｖｉｉｉ因子模倣抗体
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3735112B2 (ja) * 1992-08-27 2006-01-18 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 凝血性蛋白質に特異的な抗体、未変性蛋白質を単離するためのそれらの利用、その蛋白質の蛋白質分解性開裂産物を含まない凝血性組成物
DK128093D0 (da) * 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
EP1001991A4 (en) * 1997-07-03 2005-01-26 Smithkline Beecham Corp CRYSTALLINE STRUCTURES OF FAB ANTI-FACTOR IX FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
PT1107996E (pt) * 1998-08-28 2002-10-31 Genentech Inc Anticorpos humanos anti-factor ix/ixa
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity

Also Published As

Publication number Publication date
US7033590B1 (en) 2006-04-25
CA2384660A1 (en) 2001-03-22
WO2001019992A3 (en) 2001-09-27
RU2002109586A (ru) 2004-03-10
CZ2002935A3 (cs) 2002-08-14
CN1390258A (zh) 2003-01-08
ATA157699A (de) 2004-01-15
ES2288873T3 (es) 2008-02-01
HUP0203750A3 (en) 2005-01-28
WO2001019992A2 (en) 2001-03-22
JP2003509049A (ja) 2003-03-11
US7279161B2 (en) 2007-10-09
DE60035356T2 (de) 2008-02-14
EP1220923B1 (en) 2007-06-27
EP1220923A2 (en) 2002-07-10
SK3662002A3 (en) 2002-07-02
JP4313531B2 (ja) 2009-08-12
JP2006111638A (ja) 2006-04-27
PL354976A1 (en) 2004-03-22
ATE365799T1 (de) 2007-07-15
AU7775900A (en) 2001-04-17
AT411997B (de) 2004-08-26
AU780775B2 (en) 2005-04-14
DE60035356D1 (de) 2007-08-09
US20050196397A1 (en) 2005-09-08

Similar Documents

Publication Publication Date Title
HUP0203750A2 (hu) IX Faktor/IXa faktor ellenanyagok és ellenanyag származékok
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
NO20015504L (no) Ureasubstituerte imidazokinoliner
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
DE69907977D1 (de) Pyrrolobenzodiazepine
SG157952A1 (en) Small molecule antagonists of bcl-2 family proteins
CR6540A (es) Trifluorobutenos nematicidas
ATE253351T1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
UA85368C2 (ru) Применение остеопонтина для лечения и/или предотвращения неврологического заболевания
HUP0401658A2 (hu) Humán szöveti faktor ellenanyagok
DK1040119T3 (da) Hemiasterlinanaloger
EA199800367A1 (ru) Таблетка меченной изотопом мочевины
TR200201459T2 (tr) Okzkarbazepin içeren süspansiyon
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
ES2186807T3 (es) Inhibidores de trombina.
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
CY1110444T1 (el) Μεθοδοι μετατροπης ισομορφων των ιντερφερονων και προϊοντων τους
AU2003259159A1 (en) N-aryl-2-oxazolidinones and their derivatives
TR200103126T2 (tr) Yapısal titremenin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri
DE50212676D1 (de) Exopolysaccharidproduktion